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generally accepted that endothelial dysfunction, including blood-brain barrier (BBB) failure, is
pivotal in the pathophysiology. Recent years have seen increasing use of imaging, primarily dynamic
contrast-enhanced magnetic resonance imaging, to assess BBB leakage, but there is considerable
variability in the approaches and findings reported in the literature. Although dynamic contrast-
enhanced magnetic resonance imaging is well established, challenges emerge in cSVD because of
the subtle nature of BBB impairment. The purpose of this work, authored by members of the
HARNESS Initiative, is to provide an in-depth review and position statement on magnetic resonance
imaging measurement of subtle BBB leakage in clinical research studies, with aspects requiring
further research identified. We further aim to provide information and consensus recommendations
for new investigators wishing to study BBB failure in cSVD and dementia.
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Cerebral small vessel disease (cSVD) is an umbrella term
that covers all pathological processes of the small vessels in
the brain [1]. The most common form is age-associated and
vascular risk factor–associated microangiopathy, which may
manifest as acute symptoms (lacunar stroke), as slowlyeimer’s Association. This is an open access article under the CC BY license
Fig. 1. Schematic diagram showing the neurovascular unit. Leakage of
gadolinium-based contrast agent (GBCA) molecules across the blood-
brain barrier, from the capillary blood plasma space (volume fraction vp)
to the extravascular extracellular space (volume fraction ve), is illustrated
by the arrow. The rate of leakage per unit tissue volume and per unit capil-
lary blood plasma GBCA concentration is described by the permeability–
surface area product (PS).
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gait disturbances, and in magnetic resonance imaging
(MRI)–visible structural brain changes, such as white matter
hyperintensities (WMHs), enlarged perivascular spaces,
small subcortical infarcts, and cerebral microbleeds [2]. It
is generally accepted that endothelial dysfunction plays a
pivotal role in the early development of cSVD, and there is
consequently growing interest in the use of advanced neuro-
imaging methods to provide quantitative functional informa-
tion such as cerebrovascular reactivity, cerebral blood flow
(CBF) and pulsatility, and blood-brain barrier (BBB) integ-
rity [3]. Such techniques provide quantitative information on
changes of the cerebrovascular system including the micro-
vasculature that may predate the subsequent emergence of
classic radiological and clinical signs of cSVD and are there-
fore particularly relevant for mechanistic studies and as spe-
cific endpoints in clinical trials of drugs with relevant modes
of action, for example, those with effects on endothelial
function [4].
Although evidence is presently limited, several studies of
patients with small subcortical infarcts or vascular cognitive
impairment due to cSVD have suggested that slightly
increased BBB leakage is associated with clinical or imag-
ing features of cSVD. This points to an important potential
pathophysiologic role for BBB failure in the development
of brain tissue damage and the progression of these features
over time [1]. BBB integrity is therefore an important target
for assessment in studies of pathophysiology and could have
an important role in the evaluation of treatment. However,
the supposed elevation in BBB permeability associated
with cSVD, aging, or dementia is expected in general to
be very subtle and is therefore much more difficult to capture
than the gross disruption of the BBB seen with acute inflam-
mation, neoplasms, or infarction. Unlike these other pathol-
ogies, where signal changes are conspicuous on T1-weighted
(T1w) or fluid-attenuated inversion recovery (FLAIR) scans
after administration of gadolinium-based contrast agents
(GBCAs), the effect of cSVD-related BBB degradation on
post-contrast MRI signal changes is smaller and will there-
fore likely benefit from the application of sophisticated
quantification methods. The structure of the BBB and slow
leakage of GBCAs are illustrated schematically in Fig. 1.
For quantitativemeasurement, dynamic contrast-enhanced
MRI (DCE-MRI) has been the imaging technique of choice for
assessing BBB failure in cSVD and in other low-permeability
applications [5,6]. In this method, the slow accumulation of
paramagnetic GBCAs in the extracellular extravascular
space (EES) is detected via the T1-shortening effect on tissue
water. As shown in Fig. 2, the vascular and extravascular con-
tributions to the signal enhancement can be separated by
measuring theGBCAconcentration in both a vessel (“vascular
input function [VIF]”) and the tissue; the tissue concentration
can then be fitted using a pharmacokinetic model to separate
the vascular and extravascular components. Careful applica-
tion of this approach can yield quantitative estimates of the
BBB leakage rate (per unit volume and blood plasma GBCAconcentration), the blood plasma volume fraction, and other
physiological measures [8].
The HARNESS (HARmoNising Brain ImagingMEthodS
for VaScular Contributions to Neurodegeneration; www.
harness-neuroimaging.org) Initiative was formed in 2016,
funded by the multinational Joint Programme–Neurodegen-
erative Disease Research (JPND). The objective of
HARNESS is to standardize and disseminate neuroimaging
acquisition and analysis protocols formeasuring the contribu-
tions of vascular disease to dementia and neurodegeneration
[9]. As a component of this initiative, a subgroup convened on
four occasions in 2017 to consider emerging techniques for
BBB leakage imaging, comprising experts in magnetic reso-
nance (MR) physics, neuroradiology, and neurology. This
article reflects the outcomeof thesemeetings, and itwill focus
on the DCE-MRI approach as being, currently, the most
evolved and promising technique for obtaining quantitative,
local estimates ofBBB leakage in brain tissue.We also briefly
address other imaging and nonimaging approaches to assess
BBB integrity, such as MRI quantification of water exchange
rates and biochemicalmethods, noting that someof thesemay
deserve greater prominence in future following further tech-
nical development and validation. Although cSVD is the clin-
ical focus of this work, we have referred to technically
relevant work in other diseases. In Section 2, we summarize
applications in cSVD and assess the technical progress of
this potential imaging biomarker (IB). In Section 3, we then
provide detailed explanations of the image acquisition and
data analysis steps, highlighting the diversity of approaches
taken and the challenges and uncertainties associated with
each. Where possible, we provide recommendations for ob-
taining BBB leakage measurements in future clinical studies
of cSVD and dementia as a step toward standardization.
Where possible, these are based on evidence from the litera-
ture. Where sufficient good-quality evidence is lacking, we
aimed to put forward consensus-based recommendations as a
starting point for further development and to reduce
Fig. 2. Illustrative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data in two patients with cerebral small vessel disease (cSVD) with a
history of nondisabling stroke showing estimated concentrations of gadolinium-based contrast agent (GBCA) in blood plasma (cp, blue), white matter (Ct,
black), and the fitted Patlak model (dashed line). Data were acquired and processed by the authors using the following protocols: (A) 1.5-T MRI with bolus
injection of 0.1 mmol/kg gadoteric acid and a three-dimensional spoiled gradient echo (sGRE) sequence (acquired spatial resolution 0.94! 1.25! 4 mm,
temporal resolution 73 s, post-injection acquisition time 24 min) and variable flip angle T1 measurement; the median signal from a semiautomatically generated
normal-appearing white matter mask was fitted [7]. (B) 3-TMRI with 3-minute slow injection of 0.1 mmol/kg gadobutrol, 3D sGRE (acquired spatial resolution
2 mm isotropic, temporal resolution 40 s, DCE-MRI acquisition time 21 minutes), and T1 and flip angle measurement via the DESPOT1-HIFI method; the mean
white-matter signal from a region drawn manually in the centrum semiovale was modeled. Blood GBCA concentration (“vascular input function” [VIF]) was
sampled in the superior sagittal sinus. The derived Patlak model parameters vP and PS represent the capillary blood plasma volume fraction and the
permeability–surface area product, respectively.
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data acquisition and analysis procedures for which there is
insufficient evidence to provide firm recommendations and
where further basic methodological research is needed. In Sec-
tion 4, we address practical aspects of imaging cognitively
impaired patients. Finally, in Section 5, we locate the technique
within an IB framework [10], identifying three priority areas for
future development.2. Summary of clinical studies and methods
2.1. DCE-MRI studies in cSVD
DCE-MRI has been used to assess BBB permeability ef-
fects in several cSVD and other related conditions, including
vascular cognitive impairment [11,12], Binswanger’s
disease [13,14], cognitive impairment and dementia [11–13,15–20], small-vessel stroke and minor stroke
[7,12,14,18,21–26], type 2 diabetes [27], and aging [17].
An overview of the acquisition and analysis methods used
in clinical studies and their findings in relation to cSVD is
provided in Table 1.
Some studies assessed the relationship between cSVD
and BBB leakage by comparing patients with lacunar (i.e.,
small vessel) stroke and those with cortical stroke, reporting
variously lower [26] and higher [23,25] BBB leakage in the
white matter (WM) and greater leakage of GBCA into the
cerebrospinal fluid (CSF) [23,26]. BBB leakage has also
been studied in relation to WMH burden or total cSVD
score [32] as indicators of disease burden, with some studies
showing a positive association [21,22,26,31] between BBB
leakage and disease burden and other studies reporting
negative or nonsignificant associations between WMH
volume and leakage in various brain tissue types [13,18].
Table 1
Summary of methods and clinical findings from DCE-MRI studies of cSVD
First author (year) Participants (n) Contrast agent Acquisition Processing Main findings
Bronge (2000) [20] Dementia/cognitively
impaired with
WMH (10)
0.2 mmol/kg
gadodiamide
1.5 T; spin-echo and
sGRE;
Dt 5 10 min;
TA 5 30 min
Change in signal and
WMH/NAWM
signal ratio
No increase in either
variable after
contrast injection
Hanyu (2002) [14] BD (17), minor stroke
(10), age-matched
controls (14)
0.1 mmol/kg
gadopentetic acid
1.5 T; pre-injection
and 15-min-post-
injection 2! TR
fast spin-echo T1
mapping
Relative T1 change Greater T1 reduction
in WMH in BD
than NAWM in
controls or WMH
in minor stroke;
positive association
with cognition in
BD patients
Wang (2006) [19] MCI (11), age-
matched controls
(11)
15 s manual injection
1 mL/10 lb
gadodiamide
1.5 T; sGRE;
Dt 5 25.5 s;
TA 5 5 min
“BBB permeability
index” derived
from late
enhancement
No significant
intergroup
differences; no
association with
age or cognition
Wardlaw (2008) [25]
Wardlaw (2009) [23]
Wardlaw (2013) [24]
Lacunar or mild
cortical ischemic
stroke (100)
40 mL bolus
gadodiamide
1.5 T; sGRE;
Dt 5 69 s;
TA 5 30 min
Mixed linear model of
signal enhancement
Enhancement greater
in lacunar versus
cortical stroke in
WM and CSF;
association (in
basal ganglia) with
worse outcome
Starr (2009) [15] AD (15), healthy older
people (15)
20 mL bolus
gadopentetic acid
1.5 T sGRE;
Dt 5 3 min 46 s;
TA 5 30 min
Mixed linear model of
signal
No significant
difference between
groups; significant
time-AD
interaction effect
on signal
Topakian (2010) [22] Lacunar syndrome
with MRI infarct
(28), controls (21)
40 mL gadodiamide
bolus
1.5 T; sGRE;
Dt 5 65 s;
TA 5 28 min
Area under signal
enhancement curve
Greater AUC in the
cSVD group in
NAWM; WMH
burden predicts
AUC in NAWM
and CSF
Israeli (2011) [28] Ischemic stroke (34) Not specified 3 T; spin-echo T1w;
Dt 5 7 min;
TA 5 14 min
Images and
subtraction maps
used to calculate
“BBB opening
score”
Lower BBB opening
score in lacunar
versus nonlacunar
stroke lesions
Taheri (2011) [11] VCI (60), controls
(20)
0.025 mmol/kg bolus
gadopentetic acid
1.5 T; serial T1
mapping (TAPIR);
Dt 5 3.5 min;
TA 5 25 min
Patlak model; VIF in
SSS
WM Ki higher versus
controls; no
association with
age or CSF albumin
Huisa (2015) [13] VCI with BD (22),
age-matched
controls (16)
0.025 mmol/kg bolus
gadopentetic acid
1.5 T, 3 T; serial T1
mapping (TAPIR);
Dt 5 2.5–3.5 min;
TA 5 22.5–
24.5 min
Patlak model with
threshold to
generate “abnormal
WMP”
WMP higher versus
controls; no
correlation with
WMH load;
minimal overlap of
WMP regions at
initial and follow-
up scans
Montagne (2015) [17] NCI (24), MCI (21) 0.05 mmol/kg
gadobenic acid
3 T; sGRE T1 mapping
and dynamic scan;
Dt 5 15.4 s;
TA 5 16 min
Patlak model; VIF in
common carotid
artery
Age-dependent
increase in
hippocampal KTrans
among NCI only;
hippocampal
KTrans, CSF/plasma
albumin ratio, and
sPDGFRb higher in
MCI
(Continued )
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Table 1
Summary of methods and clinical findings from DCE-MRI studies of cSVD (Continued )
First author (year) Participants (n) Contrast agent Acquisition Processing Main findings
Heye (2016) [7] Lacunar or mild
cortical ischemic
stroke (264)
0.1 mmol/kg bolus
gadoteric acid
1.5 T; sGRE T1
mapping and
dynamic scan;
Dt 5 73 s;
TA 5 24 min
Patlak model; VIF in
SSS
KTrans greater inWMH
versus NAWM
Munoz Maniega
(2017) [21]
Signal enhancement
slope
Signal enhancement
slope in WM
increases with
WMH burden
Wardlaw (2017) [26] Mixed linear model of
signal enhancement
with time
interaction terms
Slope in NAWM
increases with age
and WMH burden
van de Haar (2016)
[29]
van de Haar (2016)
[30]
Early AD (16),
controls (18)
0.1 mmol/kg bolus
gadobutrol
3 T; SR-sGRE T1
mapping and dual
temporal resolution
dynamic scan;
Dt 5 3.2/31.8 s;
TA 5 25 min
Patlak model; VIF in
SSS; histogram
analysis to estimate
“leakage volume”
(vL)
Higher GM Ki and vL
in AD, negatively
associated with
CBF in patients
Zhang (2017) [12]
Zhang (2018) [18]
mVCI and lacunar
stroke (80), age-/
sex-matched
controls (40)
0.1 mmol/kg bolus
gadobutrol
3 T; SR-sGRE T1
mapping and dual
temporal resolution
dynamic scan;
Dt 5 3.2/30.5 s;
TA 5 24 min
Patlak model;
VIF in SSS;
histogram analysis
to estimate vL
vL but not Ki higher in
cSVD; lower Ki,
higher vL in WMH
associated with
WMH volume but
not cognition in
cSVD; Ki in GM
and NAWM not
associated with
WMH volume.
Li (2018) [31] Participants
presenting to
neurology
department
(diseases/
symptoms not
specified; 99)
0.1 mmol/kg bolus
unspecified GBCA
3 T; sGRE T1 mapping
and dynamic scan;
Dt 5 3.8 s;
TA 5 3.5 min
Patlak model;
VIF in SSS
KTrans positively
associated with
cSVD burden and
individual cSVD
features
Abbreviations: AD, Alzheimer’s disease; AUC, area under curve; BBB, blood-brain barrier; BD, Binswanger disease; CSF, cerebrospinal fluid; cSVD, cerebral
small vessel disease; DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; Dt, temporal resolution; GBCA, gadolinium-based contrast agent;
GM, gray matter; Ki5K
Trans/(1 2 Hct); KTrans, volume transfer constant; mVCI, mild vascular cognitive impairment; NAWM, normal-appearing white matter;
NCI, no cognitive impairment; PS, permeability–surface area product; sPDGFRb, soluble platelet-derived growth factor receptor b; sGRE, spoiled gradient echo;
SR, saturation recovery; SSS, superior sagittal sinus; TA, DCE-MRI acquisition duration; TAPIR, T1 mapping sequence with partial inversion recovery; VCI:
vascular cognitive impairment; VIF, vascular input function; WM, white matter; WMH, white matter hyperintensity; WMP, white matter permeability.
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reporting greater leakage in the disease groups
[11,13,14,17,22,30] and, in two studies, no significant
difference in the leakage rate [12,19]. One study reported
an association between BBB leakage and worse functional
outcome at long-term follow-up [24].
Many studies reported leakage measures in both normal-
appearing WM and WMH, although few reported on
whether the difference was statistically significant. One
study did report significantly greater leakage in WMH
versus normal-appearing WM [7], including greater leakage
with increasing proximity to the WMH [26], whereas
another study reported no significant difference [20]; other
studies quoted lower [12] and higher [14,30,31] leakage
rates in WMH versus normal-appearing WM.
Although there is a degree of convergence in the literature
regarding the relevance of BBB permeability in cSVD, there
is, as described above and in Table 1, significant variation in
both methodology and results, including order-of-magnitudedifferences in reported leakage rates [16]. A number of ef-
fects may explain the variation in reported findings. Some
of these are pertinent to clinical studies in general, including
sample size considerations (n 5 10–264 patients), study
design, and differing approaches to statistical analysis and
correction for risk factors and other variables. For cSVD
studies, participants are recruited through a variety of path-
ways and from various populations, including patients pre-
senting with cognitive impairment, acute stroke, or
dementia; participants may be in various stages of the dis-
ease process.
Importantly, the lack of a common approach to measuring
BBB failure by MRI presents a substantial additional barrier
to comparison and interpretation of the data. Awide range of
acquisition protocols, analysis techniques, and “leakage” or
“permeability” metrics (Table 1) have been used in these
studies. To an extent, these approaches may represent
different measures of the same underlying physiology and
of different aspects of BBB function; however, some
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ical and instrumental factors and may therefore be inade-
quate indicators of BBB integrity. Fortunately, there has
been moderate but significant methodological progress
over the past several years, with a small number of publica-
tions beginning to identify and address the technical limita-
tions [7,33–36], which, while somewhat well known within
the DCE-MRI field, can be particularly salient in the situa-
tions of subtle vessel permeability considered here. These
limitations, the diversity of approaches noted above, and
steps toward more targeted and harmonized IBs of subtle
BBB failure are discussed in the following sections.2.2. Alternative methods for assessing BBB leakage
Several alternative imaging-based methods for detecting
subtle BBB leakage have been proposed. Dynamic suscepti-
bility contrast (DSC-) MRI (“perfusion MRI” or “first-pass
perfusion MRI”) has been proposed for characterizing
BBB leakage in oncology [37] and stroke [38–40].
However, the typically short acquisition time, the difficulty
of modeling the effects of contrast agent on both T2* and
T1, which have a strong dependence on microstructural
properties such as vessel size, and the challenge of
disentangling perfusion and leakage effects make
quantitative evaluation with DSC-MRI particularly chal-
lenging in cSVD, where the leakage rate is typically orders
of magnitude lower than in tumors [41,42].
Multicompartment modeling of the arterial spin labeling
signal provides a potential route to measuring BBB perme-
ability to water by separating the intravascular and extravas-
cular contributions based on the different diffusion [43–45]
or transverse relaxation [46–48] properties of the two
compartments. A method for estimating global water BBB
permeability has also been recently proposed, derived
from the arterial spin labeling signal measured in veins
[49]. Arterial spin labeling–based methods have the impor-
tant advantage of not requiring GBCA administration, but
sensitivity limitations are currently a barrier to reliable mea-
surement in gray matter (GM) and especially in WM. Water
exchange dynamics can also be probed via their effect on the
spoiled gradient echo (sGRE) signal after GBCA adminis-
tration [50]. However, the relationship between water
permeability and BBB integrity, in the sense of the BBB’s
protective function, is uncertain. Abnormal water perme-
ability may in fact signify distinct and multiple physiolog-
ical aspects such as aquaporin function and metabolic
turnover. Finally, GBCA-induced enhancement of CSF on
T2w-FLAIR and T1w images allows detection of leakage
through the BBB or blood-CSF barrier [23,51]. This
approach provides qualitative leakage information, not
tissue leakage rates, but may be straightforward to use as a
marker of leakage that may be clearly visible using
standard structural sequences. Presently, it remains unclear
through which route pericortical CSF enhancement is
achieved, whether through BBB defects via perivascularspaces [23] and thence to the ventricles or cortical surface,
or via defects in the blood-CSF barrier, for instance in the
choroid plexus, or via both pathways. Such measurements
have been performed hours or even days after administration
of contrast [52,53], which illustrates the slow nature of the
leakage and may suggest that in practice, imaging does not
need to be performed immediately after contrast
administration.
Subtle leakage has also been measured previously using
the 68Ga ethylenediaminetetraacetic acid (68Ga EDTA)
tracer with positron emission tomography [54–58], but the
use of ionizing radiation, high costs, lack of available
infrastructure, and limited spatial resolution have limited
their use in cSVD research. Computed tomography
methods have also been reported [59,60], but these
approaches also carry risk from radiation dose and require
iodinate contrast agent administration. A key advantage of
MRI-based approaches is the opportunity to additionally
characterize a range of structural cSVD features with high
resolution and contrast-to-noise ratio (CNR) to assess the pa-
tient cSVD burden and to segment relevant regions of inter-
est for BBB leakage measurement.
Many nonimaging studies have assessed BBB disruption
in normal aging, dementia, and vascular disease using
biochemical methods in CSF or plasma [5,61], primarily
via the CSF/serum albumin ratio. However, such global
markers, as well as being invasive, do not provide
information on the rate, anatomical locations, or tissue
classes associated with BBB leakage.2.3. Accuracy and reproducibility
Owing to the lack of reliable, convenient reference
methods, there have been few attempts to validate or
compare DCE-MRI measurements of subtle leakage against
other techniques in humans. Taheri et al. reported a signifi-
cantly higher CSF albumin index and higher leakage rate
measured by DCE-MRI among cognitively impaired pa-
tients with “suspected microvascular disease with extensive
WM involvement” versus controls but did not find a signif-
icant correlation between the two measures [11]. Montagne
et al. reported a correlation between both the CSF/plasma al-
bumin ratio and a marker of pericyte dysfunction (CSF
platelet–derived growth factor receptor b) with DCE-MRI
leakage rates in the hippocampus among two age-matched
groups (combined) of participants with mild and no cogni-
tive impairment respectively; however, significant associa-
tions with leakage rates measured in other brain regions
were not reported and the effects of partial volume artifact
in these small regions of interest and of inflow effect on
the VIF are unknown [17]. Additional corroborative data be-
tween blood, CSF, or histological (e.g. Evans Blue, tissue
fibrinogen, Claudin-5, or immunoglobulin G) markers of
BBB failure and DCE-MRI in humans or in rodent models
or validation using custom-built phantoms with appropriate
hemodynamic and permeability characteristics would
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absence of such validation, sources of systematic errors in
such measurements in humans have been explored and
will be discussed in the following sections [7,33,35,62].
Further information on reproducibility would also aid
development as a quantitative IB but requires repeated
administration of GBCA and is likely to depend on the
acquisition and processing methods used. We are aware of
only one reproducibility study reported in the literature to
date [36], which found, among a group of patients with
mixed cerebrovascular diseases scanned at 3 T, coefficients
of variation of 11.6 % and 14.4 % for WM and GM leakage
rates, respectively.3. Review of methodology and HARNESS
recommendations
In the following sections, we review key aspects of subtle
BBB leakage measurement by DCE-MRI, including the
main challenges, uncertainties, and pitfalls associated with
each acquisition and processing step (summarized in
Fig. 3).Where possible, we provide consensus recommenda-
tions for current practice and identify aspects where further
primary research is needed to support future recommenda-
tions—these recommendations are summarized in Table 2.
3.1. MRI hardware
DCE-MRI measurements of subtle leakage are feasible at
both 1.5 T and 3 T, and there is presently no published evi-
dence indicating the benefit or otherwise of increased mag-
netic field strength. Although the influence of field strength
on the signal-to-noise ratio is well understood, the effect on
errors in the leakage rate is complex and mediated by field
strength–dependent differences in the pre-contrast longitudi-Fig. 3. Schematic block diagram illustrating the steps required to quantify subtle
during the pilot phase or as part of quality assurance procedures. Abbreviations: B
resonance imaging; GBCA, gadolinium-based contrast agent; KTrans, volume tra
function.nal relaxation rate T1,0, contrast agent relaxivity r1 [63,64],
transmit and receive coil inhomogeneity, and other factors;
additional studies including numerical simulations of these
effects would help to assess the influence of magnetic field
strength. Because the signal changes measured are typically
close to the noise level, future hardware developments that
increase CNR while preserving stability and homogeneity
will likely improve the precision of leakage measurements.
It is plausible that imaging at 3 T and 7 T will, in some
scenarios, yield increased CNR and greater precision of
leakage parameters or, alternatively, facilitate scanning at
higher spatial resolution with reduced partial volume
artifact compared with 1.5-T imaging. Scanning at higher
field also facilitates structural scanning at higher spatial res-
olution, which is likely to result in better evaluation of BBB
changes in relation to cSVD features, including WMH and
enlarged perivascular spaces. Temporal stability and artifact
level are also crucial hardware considerations because of
the very small signal enhancement and signal change
observed. Use of high-sensitivity radiofrequency receive
coilswith a high number of elements and appropriate padding
to restrict head motion is also likely to be beneficial. Finally,
the capability to achieve a high maximum gradient strength
and slew rate ensures short minimum echo times, which
reduce confounding T2* effects of the GBCA.
3.2. Pulse sequences
A three-dimensional MRI pulse sequence is recommended
to maximize the signal enhancement changes relative to the
noise level, to reduce the effect of inflow artifact on the VIF
and to obtain adequate spatial resolution and coverage within
an acceptable scan time. Use of both three-dimensional sGRE
(also known as “SPGR,” “FLASH,” and “T1-FFE”; e.g. [26])
and three-dimensional saturation-recovery sGRE (SR-sGRE;BBB leakage of GBCA. The steps indicated above the arrow are performed
BB, Blood-brain barrier; DCE-MRI, dynamic contrast-enhanced magnetic
nsfer constant; PS, permeability–surface area product; VIF, vascular input
Table 2
Summary of the main HARNESS consensus recommendations for implementation and future development of BBB leakage imaging
Category Recommendations Research questions and objectives
MRI hardware  1.5 T or 3 T
 Head coil with high sensitivity and homogeneity
 Maximal temporal stability in signal and B1
 Padding to restrict head motion
 QA program including “sham” DCE-MRI without
contrast in volunteers
 Influence of field strength on precision
 Application/development of motion reduction/
compensation techniques
Pulse sequence  3D spoiled gradient echo or 3D saturation-recovery
spoiled gradient echo
 Reliable pre-injection T1 measurement
 Effect on precision
 Influence of flip angle inhomogeneity
 Artifact reduction
Acquisition parameters  Spatial resolution sufficient to determine VIF and
smallest structures of interest without partial volume
artifact
 Temporal resolution 1 min or better
 15-20 minute DCE-MRI acquisition time
 Influence of sequence parameters and injection
protocol on precision and accuracy
Contrast agent  Standard dose of low–molecular weight GBCA
 Selection based on latest appropriate (e.g., EMA/
FDA) safety guidance
 Novel, safe contrast agents with greater T1 relaxivity
and BBB permeability
 Development and validation of non-exogenous
contrast methods
Preprocessing  Spatial realignment of time series
 Signal-concentration conversion, using pre-contrast
T1 measurement if available
 Utility of flip angle correction
 Influence of water exchange rates
 Tissue dependence of relaxivity
Pharmacokinetic modeling  Fit time-concentration data to appropriate
pharmacokinetic (typically Patlak) model
 Causes and correction of signal drift
 Spatiotemporal noise structure
Vascular input function  Measurement of individual patient VIF in a large
venous sinus
 Evaluation of signal phase for estimating VIF
Regional measurement  Report representative PS (KTrans) measurements for
each region or tissue
 Minimize cross-contamination between tissues due to
partial volume artifact and image misregistration
 Development and validation of postprocessing
methods to reduce influence of noise and artifact in
parameter maps
Biological interpretation
and reporting
 KTrans or PS reported as “leakage rate” of the GBCA
 Full reporting of DCE-MRI and T1 measurement
acquisition and analysis (Table 3)
 Data on precision and accuracy of PS including
validation against other measures of BBB integrity
 Reliable measurement of capillary surface area in vivo
Abbreviations: BBB, Blood-brain barrier; DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; GBCA, gadolinium-based contrast agent;
KTrans, volume transfer constant; PS, permeability–surface area product; VIF, vascular input function.
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time and repetition time permits faster imaging, but there is
no evidence to indicate which of these sequences is more sen-
sitive to BBB leakage. Furthermore, despite knowledge of the
equations governing the signal intensity of these sequences as
a function of relaxation times and acquisition parameters,
determination of the optimal sequence and parameters for pre-
cise measurement of subtle leakage are not trivial and thus
further theoretical and experimental exploration is required.
Although DCE-MRI typically consists of serial signal in-
tensity measurements, from which T1 changes are calculated
via the signal enhancement relative to baseline, some re-
searchers have instead directly obtained a series of quantita-
tive T1 measurements [65]. The latter approach may
ameliorate some of the effects of scanner instability and
coil inhomogeneity, as well as changes in T2* (since the
signal is not normalized to the pre-contrast signal intensity),
but T1 relaxationmaps take significantly longer than T1w im-
ages to acquire. This approach may in principle be suited to
long acquisitions when subjects are removed from the scan-
ner between measurements or where the DCE-MRI scans
can be interleaved with other (e.g., structural) MRI se-quences. Dynamic acquisitions acquiring data continuously
for longer than 15-20 minutes might increase detectability as
more contrast enters the brain parenchyma or CSF; however,
the benefits of extending the acquisition time will be limited
by practical considerations such as cost and patient tolera-
bility, and by renal clearance of GBCAs.
Finally, accurate quantification of T1 change and GBCA
concentration requires knowledge of the pre-injection tissue
and blood T1 [33] values with ideally the same spatial reso-
lution and coverage as the dynamic acquisition; a minor
drawback of this approach is the additional time and
complexity needed to accurately and precisely measure T1
in both flowing and stationary tissues. Alternatively, litera-
ture T1 values may be used to reduce the examination
time, but it should be noted that parenchymal T1 has a known
association with cSVD burden and risk factors [26] and
could therefore confound leakagemeasurements if incorrect,
whereas blood T1 varies with age and hematocrit [66,67];
assumed T1 values may therefore not be advisable in this
context if reliable T1 measurements can be made. Variable
flip angle sGRE and variable saturation-recovery delay
SR-sGRE have been used to measure pre-contrast T1
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highly sensitive to flip angle inhomogeneity and
inaccuracy [68]. Investigators should consider the impact
of flip angle variation on both T1 and DCE-MRI measure-
ments and, if necessary and feasible, perform a correction
using a reliable flip angle mapping method [69,70].3.3. Acquisition parameters
DCE-MRI of the whole brain or, at minimum, the basal
ganglia, periventricular tissues, and centrum semiovale
from anterior to posterior regions is recommended for
studies of cSVD. The spatial resolution required depends
on the study aims but should be sufficient to resolve the
smallest structures, tissues, or lesions of interest with mini-
mal partial volume artifact. For all studies, the resolution
and orientation should be such that at least one major blood
vessel is clearly resolved for measurement of the VIF. Ac-
quired voxel volumes of 2-10 mm3 are typical. For a three-
dimensional acquisition, Gibbs artifact propagates in all
three dimensions; therefore, thick slices should be avoided
to reduce the impact on parameter maps [7].
An imaging volume with axial orientation typically per-
mits faster sampling if inferior brain regions such as the pos-
terior fossa are not of interest; however, slab-selective
excitation of an axial imaging volume may result in blood
inflow artifact in the VIF. This effect can be reduced via
sagittal or coronal acquisition. The use of spatially nonselec-
tive excitation will further reduce inflow and may increase
uniformity of the excitation profile.
Unfortunately, it is challenging to achieve the above
spatial requirements with both a rapid sampling rate and
acceptable CNR using currently available 1.5-T and 3-T
MRI scanners. As a consequence, the rapid concentration
changes following a bolus injection of GBCA are difficult
to resolve. For subtle leakage measurement, the primary
justification for high temporal resolution sampling is to mea-
sure the high and rapidly changing GBCA concentrations in
blood during the first pass, so that leakage occurring during
this period can be modeled. However, the error caused by
temporal undersampling of the first pass can be assessed
via simulations and it has been shown that this may be small
with a temporal resolution on the order of one minute [7]. In
an alternative approach, the first pass is sampled at higher
temporal resolution with consequently reduced spatial
coverage and/or spatial resolution during the early circula-
tory phases [30]. This approach increases the complexity
of the acquisition, but provided the spatial and temporal res-
olutions are sufficient to accurately measure concentration
in a large vessel, the contribution of leakage during the first
pass can be appropriately modeled. A third option is to
perform a slow injection of GBCA, which results in slower
early-phase blood concentration changes; this approach al-
lows the signal dynamics to be adequately sampled at lower
temporal resolution, reduces T2* effects and the range of
blood GBCA concentrations to be measured, and ensuresthat venous GBCA concentration more accurately reflects
the arterial concentration and therefore the VIF. Although
a slow injection approach has been reported previously in
the literature [19], the benefits have yet to be evaluated for
subtle BBB leakage measurement.
Although leakage rates can be measured at low temporal
resolution, there are potential benefits to limiting the scan
time for each volume: first, artifact and blurring due to pa-
tient motion and GBCA concentration change may be
reduced; second, rapid sampling of both tissue and blood
GBCA concentrations after a bolus injection permits mea-
surement of CBF as well as plasma volume fraction and
leakage rate, provided a reliable arterial (not venous) input
function can be measured and an appropriate pharmacoki-
netic model is used [71].
A final important consideration is the total scan duration.
For measurement of slow extravasation, a longer overall scan
time was shown to increase the reproducibility of leakage
measurements [36]; in practice, the acquisition time is limited
by patient cooperation (e.g., headmovement), the availability
and cost of scanning time, and the need to obtain additional
images for clinical evaluation and/or research purposes. As
the leakage rate differs between GM, WM, and lesions, the
optimal scan time may also depend on the clinical focus of
the study. As a guide, we recommend that DCE-MRI scan-
ning continues for at least 15 and preferably 20 minutes at
3 T [72]. Multiple images should also be acquired before a
contrast injection to allow reliable estimation of the GBCA
concentration, which is based on the relative signal enhance-
ment with respect to pre-contrast images [35]. The require-
ment for a relatively long acquisition time may be one
reason for the limited adoption of the DCE-MRI method in
cSVD research studies, and future evaluation of ways to
reduce the scan time would be beneficial. Interleaving of
the DCE-MRI scan with other MRI techniques (e.g., FLAIR,
T2w) to limit the total examination time, while still acquiring
DCE-MRI images at late time points, is a potential solution
but would require detailed consideration including an under-
standing of the effects of contrast agents on the interleaved se-
quences and the potential effect of any additional pre-scan
adjustments. Long acquisition times might also be achieved
more conveniently via methods that enable the patient to
leave and re-enter the MRI scanner during the experiment.
In summary, there is considerable uncertainty around the
“optimal” pulse sequence and acquisition parameters to use
and further experimental and theoretical investigation is
required. Cramer et al. and other groups used a Monte Carlo
simulation approach to generate synthetic data for a range of
pharmacokinetic parameters and incorporating various effects,
such as CBF, noise, and scanner drift; thesewere then fitted us-
ing a pharmacokinetic model to yield graphs of “measured”
versus “actual” leakage measures, to illustrate the precision
(error bars) and accuracy (deviation from the line of equality)
of the estimates [7,34]. Barnes et al. also used a simulation
approach, introducing the “K-CNR” quantity to represent the
CNR of the measured leakage rate for a 10% difference in
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both systematic and random errors in a singlemetric. All simu-
lation approaches are limited by the accuracy of the model
used to generate the ground truth data (typically the two-
compartment exchange model) and rarely account for factors
that may be substantial but difficult to predict and simulate,
such as motion, ghosting, and Gibbs artifacts, and by the
spatiotemporal noise structure.3.4. Contrast agent
The leakage rate and the accuracy and precision of its mea-
surement are likely to depend on the size, shape, and chemical
properties of the contrast agent [73,74], but at present, there is
no convincing evidence for selecting a specific GBCA for
studies of BBB integrity. On theoretical grounds, one would
prefer a contrast agent with a strong T1 relaxivity, high BBB
permeability (compared with the agents listed in Table 1),
and long biological half-life to obtain the lowest detection
limit for leakage. Binding of linear GBCAs to albumin is
another issue that deserves consideration, as it will hinder
extravasation on the one hand but will increase relaxivity
due to slower molecular tumbling. Partial protein binding
also adds uncertainty to the conversion between signal change
and GBCA concentration, as the protein concentration may
vary between compartments and tissues [75].
Because the aforementioned issues require further inves-
tigation, the choice of contrast agent should at present be
based primarily on safety considerations, including mini-
mizing the risks of nephrogenic systemic fibrosis [76] and
long-term retention of gadolinium [77–79]. Some
investigators have used a reduced dose of GBCA to reduce
“ceiling” effects on the signal enhancement during the first
pass [62,65]. For measurement of slow leakage, however,
increasing the gadolinium concentration gradient between
the vascular space and parenchyma will drive increased
transfer across the BBB and reduce the leakage detection
limit; ceiling effects can be avoided by tailoring the pulse
sequence parameters (e.g., flip angle for sGRE) during the
first pass or by reducing the injection rate. Therefore, we
recommend using the standard clinical dose of GBCA
subject to patient safety considerations.3.5. Data preprocessing
Once images have been acquired and before kinetic
modeling of the data, a number of preprocessing steps
(Fig. 3) should be performed as required. Head motion, which
is inevitable over a lengthyDCE-MRI scan, should be corrected
usingwidely available image co-registration algorithms such as
SPM Realign (https://www.fil.ion.ucl.ac.uk/spm/) and FSL
MCFLIRT [80]. The second preprocessing step is to convert
the absolute MRI signal to the signal enhancement relative to
the pre-injection intensity. Third, the signal enhancement is
converted to tissue GBCA concentration. A GBCA induces a
change in R1 (51/T1) that is approximately linearly related tothe concentrationvia aproportionality constant knownas the re-
laxivity r1. Because there is little information available
regarding the variation of r1 in different tissues, it is normally
assumed to be the same in blood and brain tissue; therefore,
the value used has no effect on the final leakage measurement.
The R1 increase in turn causes a signal enhancement that is
approximately linear at low GBCA concentrations but depen-
dent on the pre-contrast T1. We recommend this conversion
be performed using an equation that accurately describes the
MR signal of the pulse sequence used. Measured pre-contrast
T1 and, if required and available, flip angle values should be
used in such calculations instead of assumed values, particu-
larly for techniques with high B1 sensitivity such as sGRE.
For blood, the determination of GBCA concentration from
signal change can be more difficult as T2* and inflow effects
may affect the relationship, especially at the relatively high
first-pass concentrations. Measuring the phase of the MRI
signal in large vessels provides a potential alternative way to
determine the VIF, which has been proposed for DSC-MRI
and DCE-MRI measurements and could in future be explored
in this context [81,82]. Enhancement to concentration
conversion in blood can alternatively be achieved by scanning
test objects containing a range of known gadolinium
concentrations and with appropriate pre-contrast T1 values
[36], but the concentration estimates are influenced by the accu-
racy of the assumed blood T1 as discussed previously.3.6. Data analysis
Many different approaches have been reported for gener-
ating metrics of BBB integrity from DCE-MRI (Table 1) in
cSVD and other pathologies, with the outcome measures
variously labeled as “KTrans,” “permeability,” “leakage
rate,” “BBB opening score,” “BBB permeability index,”
etc. This variability impedes reliable interpretation, and
comparison and pooling of data across studies. All such
analysis methods can be categorized as either qualitative,
semiquantitative, or quantitative. Because the tissue
enhancement in cSVD is normally too small to be visible
radiologically, qualitative analysis is rarely used except to
identify visibly enhanced areas in CSF or stroke lesions.
Semiquantitative analysis has been used to probe BBB
leakage in several cSVD studies, including area-under-curve
calculation [22], mixed general linear modeling of the MRI
signal to determine differences in the signal-time curves
[23], and several other methods referred to in Table 1. Such ap-
proaches are relatively straightforward to implement and may
reflect in part variation in BBB leakage across a sample over
which the scan protocol is kept constant. However, the signal
changes after GBCA injection depend strongly on the pulse
sequence, field strength, contrast injection protocol, vascular
supply, the time delay between contrast administration and
measurement, and other factors additional to the kinetics of
GBCA leakage; the signal changes and derived semiquantita-
tive parameters are therefore not considered to be quantitative
markers of BBB leakage.
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which aim to generate (continuous) kinetic measures with
a direct relationship to the underlying tissue properties [7],
are simpler to interpret and less sensitive to the acquisition
protocol than qualitative and semiquantitative analysis;
this is particularly salient for comparison of results between
sites and for longitudinal and multicentre studies where MRI
system differences, scanner upgrades, and instrumental
instability are likely to have a smaller effect on the values
of carefully determined pharmacokinetic measures. The
aim of such analysis is normally to estimate the BBB leakage
rate by modeling the relationship between blood and tissue
GBCA concentrations as a function of tissue and GBCA
properties. In recent years, understanding and confidence
in the use of pharmacokinetic modeling for subtle BBB
leakage measurement has increased and its application has
widened. We therefore recommend this approach where
the imaging protocol is adequate to support it, for example,
availability of a high-quality VIF, and with awareness of the
limitations of this type of analysis discussed below.
3.7. Pharmacokinetic modeling
Several pharmacokinetic models are commonly used to
analyze DCE-MRI images in a range of tissues and pathol-
ogies, and it is critical to select amodel appropriate to the acqui-
sition protocol, the tissue microstructure, and the likely ranges
of the pharmacokinetic parameters [7,8,83]. Ideally, the model
should predict the total tissue GBCA concentration Ct (i.e.
including both capillaries and the EES) using the minimum
number of parameters required to properly fit the data. For
measurement of slow leakage at low temporal resolution, we
recommend the Patlak model, which has now been used by
several groups in the subtle BBB leakage literature and has
been shown to perform well in comparison to other models,
including the two-compartment exchange and extended Tofts
models [7,34,35]. The Patlak model makes two particular
assumptions: (1) GBCA concentration in capillaries is
accurately represented by VIF measurements in a large
vessel, which is justified where tissue perfusion is sufficiently
high in relation to BBB leakage and to changes in arterial
GBCA concentration, and (2) back-flux from the EES to the
capillaries is negligible, which is normally justified in subtly
leaking tissues (though not necessarily in tissues with higher
leakage rates, as found in some stroke lesions [7]) where the
plasma concentration remains much greater than that in the
EES. These assumptions lead to a simple model equation that
is conveniently linear in the two unknown parameters:
CtðtÞ5vpcpðtÞ1PS
Z t
0
cp

t
0
dt
0
; (1)
where the permeability–surface area product (PS) represents
the BBB leakage rate per unit capillary plasma GBCA con-
centration and per unit tissue volume; vp is the dimensionlessparameter representing the capillary blood plasma volume
fraction in tissue, and cpðtÞ is the GBCA concentration in
blood plasma; the latter is given as cpðtÞ5cbðtÞ=ð12HctÞ,
where Hct is the hematocrit and cbðtÞ is the GBCA blood
concentration estimated by the VIF. Example data and Pat-
lak model fits are shown in Fig. 2.
It is essential to consider the appropriateness and limita-
tions of this or any other pharmacokinetic model in relation
to the particular tissue properties and acquisition protocol
pertaining to the study. For example, the assumption of
high tissue perfusion may be inappropriate for modeling
the rapid concentration changes that occur around the time
of the first pass after a bolus injection—this inaccuracy
may be reduced by excluding the early data points from
the fitting (however, the cp values during the first pass are re-
tained to calculate the integral term of Eq. 1) [7,62]. PS
measurements in highly ischemic tissues (i.e., those with
very low CBF) could also be confounded. The further
assumption of negligible back-flux across the BBB may
also be invalid for the relatively high leakage rates some-
times found in stroke lesions and/or at long acquisition times
where the GBCA concentrations in the EES and capillaries
may be comparable; back-flux is expected to become signif-
icant as the acquisition time after injection approaches the
mean transit time for the EES, equal to ve/PS, [8] and is
likely to be (although there is no empirical data) much longer
than the recommended 15- to 20-minute acquisition time in
normal-appearing brain tissue.
To assess model suitability, we recommend that time-signal
data and model fits to concentration-time curves be inspected
visually in at least a subsample of the data; if required, simu-
lations for testing model validity should be performed and re-
ported (e.g., references [7,35,62]). Statistical approaches, such
as the Akaike information criterion, may also aid model
selection [7,84,85] but address only goodness of fit and not
the model’s physical or biological validity. Data can be fitted
using widely available nonlinear least squares minimization
algorithms, and convergence of the fit should be verified
visually in a subset of the data. Constraints to fitted
parameters should in general be avoided because noise and
artifacts can result in values that lie outside of the expected
ranges, for example, scanner drift can result in biased,
potentially even negative, leakage rate and plasma volume
fraction estimates [7,35]. The Patlak model may be fitted
with high computational efficiency using the “graphical”
Patlak approach, in which PS is determined as the slope of a
CtðtÞ=cpðtÞ versus
Z t
0
cp

t
0

dt
0
=cpðtÞ scatter plot.
Alternatively, multiple linear regression analysis can be
performed with CtðtÞ as the dependent variable and cpðtÞ
and
Z t
0
cp

t
0

dt
0
as the regressors, which is less vulnerable
to noise for small cpðtÞ than the graphical method.
Although the validity of the specific assumptions under-
lying the Patlak model can be assessed, several other
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model. For example, research is needed to determine the in-
fluence of water exchange rates across the endothelium and
cell membrane on the estimated subtle leakage rates because
water exchange is assumed to be infinitely rapid in most
pharmacokinetic models [86]. Signal drift, which may result
in comparable signal changes to those induced by any
GBCA leakage, can also have a substantial influence on
the estimated pharmacokinetic parameters [7,33,35], and
research is needed to better understand the physiological
and instrumental processes underlying drift and to develop
methods for assessment and compensation. It is therefore
prudent to perform simulations and “sham” DCE-MRI scans
without contrast to evaluate the potential impact on leakage
rate estimates. Other common assumptions, such as tissue-
independent relaxivity, instantaneous mixing of the tracer
within tissue compartments, and an equal hematocrit in large
vessels and capillaries, may also affect accuracy. Pharmaco-
kinetic models are necessarily based on a highly simplified
description of tissue microstructure and function and there-
fore can ignore potentially relevant features such as the peri-
vascular space and interstitial fluid transport.3.8. Vascular input function
An important consideration for quantitative measure-
ments is determination of the VIF because pharmacokinetic
models require knowledge of the GBCA concentration in the
blood plasma entering the tissue. Measurement in the
feeding cerebral arteries is difficult because of their small
cross-section leading to partial volume artifact and, particu-
larly for axial acquisitions, the rapid inflow of protons from
below the volume of excitation, which have not reached a
steady state, giving rise to reduced enhancement after
contrast administration and therefore inaccurate concentra-
tion estimates [71,87]. We therefore recommend VIF
measurement in a large venous sinus, such as the superior
sagittal sinus because both of these detrimental effects can
be minimized: partial volume artifact due to the increased
diameter of the lumen and inflow artifact due to the lower
blood velocity and longer time available to reach a steady
state within the excitation volume, provided this is
sufficiently large. The posterior section of the superior
sagittal sinus is also less sensitive to motion because of its
position near the fulcrum of head movement when the
subject is lying supine. In our experience, venous VIFs
have higher signal-to-noise ratio and CNR and are more
representative of blood concentration than VIFs measured
in the internal carotid or middle cerebral arteries, for the rea-
sons described previously. Although venous GBCA concen-
tration theoretically represents an “output” rather than an
input function, the arterial and venous concentration profiles
are found to be very similar following the rapid early
changes during the first pass of the bolus [71]. For the pur-
poses of applying the Patlak model, which should not in
any case be used to fit first-pass data, the superior sagittal si-nus VIF provides a good approximation to the arterial input
function. VIF voxels should be selected using the dynamic
rather than structural images to ensure good CNR and to
avoid contamination from non-blood signals.
AVIF may potentially be estimated using a mathematical
function based on population-averaged data [88–90], and
this approach avoids some of the errors inherent in patient-
specific VIF measurements. However, assumed VIF functions
do not take account of either day-to-day or intersubject differ-
ences [91] because of variation in cardiac and renal function,
body composition, and other unknown factors. Such con-
founds could potentially influence cross-sectional and longitu-
dinal analysis of BBB leakage; therefore, we recommend
measurement of a high-quality VIF in each patient.3.9. Regional measurement
Two general approaches to image analysis are commonly
used in DCE-MRI: (1) voxel-based mapping of pharmacoki-
netic parameters, which are then sampled using tissue masks
or regions of interest and (2) modeling of ROI- or tissue-
averaged signals. The first approach is, in principle, superior
because it does not assume that voxels within a tissue or re-
gion share a common set of properties, the spatial resolution
of the original images is retained, additional insight into the
spatial pattern of leakage may be obtained, and histogram
analyses of leakage parameters can be performed [12,65].
In practice, as illustrated in Fig. 4, the noise and artifact
levels for individual voxels can be substantial and may
impede the generation of reliable parameter maps; in such
cases, signal averaging to increase the CNR within regions
before pharmacokinetic modeling (as shown in Fig. 2) is
advisable and, by reducing the size of the data set, renders
visual inspection of the fit quality feasible. Mean or median
PS and vP and a measure of inter-subject variation (such as
standard deviation or interquartile range) should be reported
for each region or tissue as a minimum.
Where voxel-based analysis is performed, the low CNR
leads to leakage estimates that are frequently close to the
noise level and may often be negative. Van de Haar et al.
[12,30] illustrated the substantial noise contribution in
individual voxels resulting in negative leakage estimates in
a relatively large proportion. Using a histogram approach,
the authors attributed negative leakage values plus a
mirrored positive distribution of these voxels to noise,
whereas the remaining positive values in the histogram
were classified as having detectable leakage; the leakage
values of these “noise” voxels were set to zero before
calculation of the mean leakage rates over remaining
voxels and, additionally, the fraction of “detectably
leaking” voxels for each region was calculated. Raja et al.
agreed that noise and negative values should be addressed
but favored a different statistical procedure whereby the
Akaike information criterion is used to determine whether
the data in individual voxels support a model (e.g., Patlak)
that includes BBB leakage versus a vascular-only model
Fig. 4. (A) Illustrative 3-T PS (units min21) map in a patient with cSVD (71-year-old female) after acute lacunar stroke 6 weeks previously. For the correspond-
ing PSmap (B), the raw DCE-MRI images were smoothed using a three-dimensional gaussian kernel (full width at half-maximum 2 mm) during preprocessing
to suppress the noise and Gibbs artifact apparent in (A). In both maps, the low level of leakage is apparent, with noticeably higher values in the stroke lesion
(indicated by the cross hairs) and in the periventricular normal-appearing white matter ipsilateral to the stroke lesion. The corresponding T2w-FLAIR image is
shown in (C). DCE-MRI data were acquired and processed by the authors as described in the caption to Fig. 2B. Abbreviations: cSVD, cerebral small vessel
disease; DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; PS, permeability–surface area product.
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how this addresses the problem of a model that fits the
data well but with negative PS [16]. Another approach was
proposed by Taheri et al., who fitted a statistical distribution
to PS values measured in a sample of healthy volunteers, and
used the 95% confidence limit of this distribution to identify
voxels with “abnormal” leakage [65]. Each of these methods
has limitations leading to arbitrary classification of “leak-
ing” versus “nonleaking” or “noise” voxels that depend on
instrumental and other site- and study-specific factors
including the artifact level, CNR, the complicated noise
structure, and the characteristics of “healthy” reference sub-
jects, with the potential to bias study outcomes. The validity
of such methods in the presence of significant signal drift,
where PS measurements are likely to be offset from the
true values, is also unclear. However, for research where
the outcome measures relate to the properties of regions
and tissues, it is not essential to dichotomize voxels in this
manner, and several studies have simply averaged signals
or leakage rates across all voxels within the regions and tis-
sues of interest to reduce the effect of noise. As there is pres-
ently no consensus on voxel classification methods, a simple
averaging approach is recommended as a common “base-
line” for future studies.
The definition of region and tissue masks will depend pri-
marily on the research questions and study objectives.
Where tissue masks are used, care should be taken to avoid
contamination by adjacent structures (e.g., CSF and major
blood vessels), for example, by “eroding” the mask images.
The use of carefully placed small regions of interest is an
alternative approach that permits investigation of smallerstructures and regions while avoiding contamination but is
more observer dependent than automated methods and suf-
fers from higher noise levels.3.10. Biological interpretation
Analysis of DCE-MRI using an appropriate pharmacoki-
netic model yields estimates of the BBB leakage rate, equiv-
alent to the PS of the regional microvasculature. The
permeability P is defined as the quantity of GBCA mole-
cules leaving the capillary through the BBB per unit time,
per unit capillary wall area, and per unit capillary blood
plasma concentration of the GBCA, and the surface area S
is the total capillary wall surface area per unit tissue volume;
the product PS therefore represents the overall normalized
“leakage rate” of GBCA across the BBB, i.e., the quantity
leaking per unit time, per unit capillary plasma GBCA con-
centration, and per unit tissue volume. Because S is un-
known, it is impossible to calculate the permeability P or
to distinguish between differences or changes in the perme-
ability and differences or changes in the capillary wall sur-
face area. Currently, it is not possible to determine the
local capillary wall surface area of the brain microvascula-
ture in vivo with confidence; MR techniques for estimating
the related vessel size have been proposed [92] but are not
straightforward to implement, involve other assumptions,
and are at an early stage of development. “Leakage” and
“leakage rate” of GBCA are therefore more appropriate ter-
minology than “permeability” for describing DCE-MRI
measurements of PS. It should also be emphasized that the
leakage rate of a particular GBCA is being measured—
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plexes with low molecular weight (e.g., the molecular
weight of gadobutrol and gadoteric acid are 604.7 g mol21
and 558.6 g mol21, respectively). Thus, although PS is a
quantitative measure that is influenced by BBB integrity, it
cannot predict the BBB transport rates of specific biological
molecules in the blood such as glucose and proteins.3.11. Reporting
Reporting of the employed methodology to measure subtle
BBB leakage has sometimes been unclear and inadequate to
permit replication. Although general reporting standards for
clinical studies are well known, we recommend in particular
that full details of theMRI acquisition, contrast administration,
image processing, and pharmacokinetic modeling should be
reported in sufficient detail to enable other groups to repeat
the experiments. Reporting should include full details of the
dynamic and T1 measurement scans, image preprocessing,
VIF selection, model fitting, formulas, region and tissue
mask generation, and postprocessing and statistical analysis
of the data. In particular, the way in which the leakage value
is calculated and to which voxels and tissue regions it refers
requires attention. Where possible, individual patient hemato-
crits should be measured and used to report PS [7]. Some pub-
lications have used the alternative KTrans (defined as the
quantity of GBCA leaking across the BBB per unit time, tissue
volume, and arterial blood plasma concentration) notation,
which is interchangeable with PS provided the model assump-
tions discussed previously (e.g., high blood flow, slow leakage)
are applicable; in this case, we recommend reporting PS as a
parameter that has a clear biological interpretation. This mea-
sure should be reported in preference to Ki, which quantifies
leakage in relation to blood concentration rather than blood
plasma concentration of GBCA (because intravascular
GBCA is normally restricted to the plasma compartment). Pre-
vious reviews provide guidance on appropriate units for report-
ing such data [8,93]. We recommend to report representative
values (i.e., mean or median) and spread (e.g., standard
deviation or interquartile range) of all fitted pharmacokinetic
parameters, including vp or the related blood volume fraction
vb5 vp=ð12HctÞ. The tissue regions to which these values
pertain should be clearly described; where parameter maps
are shown, thresholds and other methods or filters used to
generate these should be noted. We recommend that the
acquisition parameters and other information summarized in
Table 3 should be reported with the study findings.4. Practical considerations for DCE-MRI in cognitively
impaired and demented subjects
DCE-MRI has been applied in several cognitive impair-
ment and dementia patient groups (Table 1), including
mild cognitive impairment, vascular cognitive impairment,
and early Alzheimer’s disease [11–15,17–20,29,30].
However, researchers should be aware that there are somepractical difficulties of studying and imaging such
patients; in particular, detection of very small signal
changes over a long acquisition requires a degree of
compliance, as DCE-MRI is sensitive to patient motion.
Anecdotally, we find that regular communication with imag-
ing staff during the examination, accompaniment before
MRI by a familiar clinician or carer, and the opportunity
to rest, move, or break between scans have a positive effect
on tolerability. Padding to reduce head motion is essential,
and real-time motion correction (e.g. navigator-based or op-
tical) scanning methods may in future increase feasibility in
less compliant subjects.
Image analysis steps including spatial normalization and
tissue segmentation also pose specific challenges in patients
with severe neurodegeneration because of variable and often
substantial levels of brain atrophy and lesion burden.
Regarding implementation, literature in the field is
confined to a relatively small number of research centers
with relevant medical physics and image processing experi-
ence. However, specialist MRI hardware and pulse se-
quences are not required for implementation, and we
believe there is now sufficient information and advice avail-
able in the literature, including in the present article, to
enable most groups with a good level of general imaging
expertise to employ the technique. To support this, MRI pro-
tocols and analysis tools for structural and quantitative imag-
ing, including DCE-MRI, are published on the HARNESS
website (www.harness-neuroimaging.org).5. Priorities for future research
O’Connor et al. described a detailed roadmap for discov-
ery, validation, and qualification of reliable IBs for use in
cancer research and health care [10], which we believe pro-
vides a useful framework for development of IBs in other
fields including cSVD and dementia. In the language of
the roadmap, our review describes an IB that has passed
through the initial “discovery” domain and now sits within
the second “validation” domain, wherein three tracks (tech-
nical validation, biological and clinical validation, and cost
effectiveness) are identified. As discussed in detail in the
preceding sections and summarized below, progress has
been made in some aspects of the validation domain, but
we believe that further research is required for DCE-MRI
measurement of subtle BBB leakage to cross the first “trans-
lational gap” whereby it can be recognized as a reliable mea-
sure for testing hypotheses in clinical research.
With regard to technical validation, there is presently
only one published study of precision in vivo [36], studies
of bias have been conducted mainly from a theoretical
standpoint and are limited in scope; however, reasonable
availability of the technique in the research setting is evi-
denced by publications from several groups globally. Bio-
logical and clinical validation has received some
attention in the literature, with several studies showing asso-
ciations between BBB integrity measures and certain
Table 3
Table of key parameters and information (not exhaustive) that should be reported where applicable
MRI acquisition  Pulse sequence used for DCE-MRI, and T1 and flip angle mapping
 Field strength, inversion/saturation-recovery delay, repetition time, echo time, flip angle
 k-space sampling scheme
 Acceleration techniques, bandwidth
 Orientation, acquisition matrix, field of view, acquired spatial resolution (including structural scans)
 Temporal resolution, acquisition time
 Signal drift
Contrast agent  Agent, concentration, dose, volume
 Injection rate, time, and delay
 Number of pre-contrast images
Preprocessing  Algorithms and formulas used for realignment, T1 calculation, concentration estimation etc.
Pharmacokinetic modeling  Model selection and justification
 Fitting method, data points excluded, constraints
 Details of simulations performed
Vascular input function  Location, size, and procedure for selecting
Regional measurement  Procedure for generating ROIs and tissue masks
 Specify the signal modeled, i.e., voxel signal or region-averaged signal
Results  Summary PS or KTrans, vP, vb, T1, and other relevant parameter values for each region
 Representative signal enhancement curves including VIF
 Representative concentration curves with model fit
Abbreviations: DCE-MRI, dynamic contrast-enhancedmagnetic resonance imaging;KTrans, volume transfer constant;PS, permeability–surface area product;
VIF, vascular input function.
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ysis protocols, and of study design, hampers comparison
and pooling of such data; evidence linking IB measurements
to the underlying biology is more sparse because of the lack
of adequate reference methods. The cost effectiveness track
has also received little attention to date: it is generally
acknowledged that the long acquisition increases costs and
discourages more widespread use, but a lack of data on pre-
cision is an obstacle to reliable calculation of statistical po-
wer and study cost. Cost-effectiveness will become more
relevant after the first translational gap has been crossed
and use of the IB in health care systems is considered.
As recommended by O’Connor et al., the three tracks
should be pursued in parallel, but in this context especially
they are interdependent and require a foundation of method-
ological research. Throughout this review and in Table 2, we
have identified specific areas requiring further research. In
the following paragraphs, we propose three areas of immedi-
ate priority for future work in the field:
1. A standardized multivendor protocol would under-
pin future studies of precision, bias, and clinical and
biological validity and facilitate wider adoption. How-
ever, despite increasing application of the technique in
clinical studies, little method development work is re-
ported in the literature, leading to a lack of objective
evidence on which to base a “consensus protocol.”
In this review, we provide several specific consensus
recommendations for acquisition and data analysis
(Table 2) with the aim of encouraging greater harmo-
nization, but there is insufficient evidence to recom-
mend a specific protocol at present. We therefore
recommend that an international working group be es-tablished to continue to work toward an open-access
consensus protocol. The group should be open to all
experts in the field, and recommendations should be
dynamic and version-controlled to represent the cur-
rent best standard and respond to emerging evidence
including from current projects by North American
(https://markvcid.partners.org), European (https://
www.svds-at-target.eu/), and global (http://www.
small-vessel-disease.org) consortia.
2. Evidence of repeatability and reproducibility
should be obtained in healthy volunteers and/or pa-
tients. The outcome variables identified in Section
3.11 should be analyzed, and the raw images ideally
made accessible to the research community to enable
testing of different analysis methods and software.
3. Further evidence of accuracy is required, including
research into bias and biological validity. Such evi-
dence would increase confidence within the cSVD
and dementia research community that measurements
are not only feasible and reproducible but reflect the
pathophysiological aspect of interest. Such investiga-
tions should include theoretical studies, comparison
with independent markers of BBB dysfunction, devel-
opment and use of suitable MRI test objects, and pre-
clinical histological validation. Further clinical studies
of BBB leakage (following the recommendations pro-
vided) in relation to disease severity, disease progres-
sion and other clinical variables would also increase
confidence in the technique.
Although the aforementioned steps are essential to estab-
lish DCE-MRI subtle leakage measurement as an IB for
research, we also encourage basic research to advance or
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sion, accuracy, and feasibility of imaging BBB dysfunction.6. Conclusions
An increasing number of clinical studies are being pub-
lished that indicate the possibility of, and growing interest
in, MRI quantification of subtle BBB dysfunction for
research into the pathophysiology of cSVD and dementia
and, ultimately, for development and monitoring of treat-
ments. As reported in this review, DCE-MRI provides at
present the most promising means for achieving this and
has yielded a number of intriguing findings in relation to
cSVD. However, the technique has been implemented
with diverse acquisition and analysis methods, which
involve many assumptions and suffer from significant,
sometimes unquantifiable, limitations that can render clin-
ical findings difficult to interpret and impede comparisons
between studies and centers. Some of the limitations stem
from the practical and technical challenges of measuring
very subtle leakage including the unfavorable CNR and
artifact characteristics of the acquired signals. Reported
BBB leakage measurements have a high variance between
research sites, as noted by Raja et al. in their recent system-
atic literature review of BBB function in dementia [16].
Their article emphasized the predominant role of DCE-
MRI with pre-contrast T1 quantification and pharmacoki-
netic modeling but further noted that reliable measurement
of subtle leakage is a particular challenge with this method;
the authors also emphasized the need for collaborative ef-
forts to harmonize data collection and analysis methods,
a task we have initiated here.
As a group with substantial collective technical and clin-
ical experience in the cSVD and MRI fields, our intention
in writing this review is to provide researchers with compre-
hensive information, advice, and consensus-based recom-
mendations for performing such measurements in research
studies, to describe the limitations so that authors and readers
may better assess the quality and implications of studies, and
to identify areas where further research and development will
benefit future clinical applications. For clarity, we note that
our recommendations are not intended as a medical guideline
and that DCE-MRI quantification of subtle BBB leakage is
not yet suitable for use as a clinical decision-making tool.
We hope that these recommendations will encourage a greater
degree of harmonization in future studies where possible, in
order that data from multiple centers can be more easily
compared and pooled. We have focused on DCE-MRI as
the method that is, at present, most advanced and most widely
used, and which we believe provides a quantitative, though
relative, measure of BBB integrity. Nevertheless, the tech-
nique is relatively immature in the context of measuring sub-
tle BBB leakage, and we note that our recommendations do
not represent the final word on the subject but rather a prag-
matic “baseline” approach that may inform the design offuture studies, lead to greater harmonization and interstudy
comparability, and provide a starting point for future initia-
tives to further standardize, develop, and validate the method.
The alternative techniques for assessing BBB integrity
described in this article may also undergo further develop-
ment and merit greater prominence in future reviews.
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1. Systematic review: This article summarizes the work
performed by an international multidisciplinary
working party that convened on four occasions,
comprising a review of the literature and proposal
of recommendations concerning future application
and development of blood-brain barrier integrity im-
aging.
2. Interpretation: Examination of the literature revealed
a high degree of methodological heterogeneity with
potential to affect the findings and conclusions of
research studies. Detailed advice and consensus rec-
ommendations are proposed to increase the quality
and harmonisation of future clinical research studies.
3. Future directions: Areas are identified where insuffi-
cient evidence precludes firm recommendations and
further research is required. Three priorities for
further development towards a reliable imaging
biomarker of subtle blood-brain barrier failure are
identified.
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